Don't forget cord blood in non-remission acute myeloid leukaemia!

Authors :: Castagna L
Patti K
Mulè A
Source :: British journal of haematology [Br J Haematol] 2023 Apr; Vol. 201 (1), pp. 11-12. Date of Electronic Publication: 2022 Dec 12.
Publication Year :: 2023
Abstract: Transplantation from haploidentical donors is widely used, with progressive reduction of cord blood (CB) as alternative donor. The paper by Matsuda and colleagues, the largest analysing the outcome in non-remission acute myeloid leukaemia (AML) transplanted with haploidentical donor or CB, suggests that CB is still a viable option when considering allogeneic transplantation for advanced AML. Commentary on: Matsuda et al. Comparison of transplant outcomes between haploidentical transplantation and single cord blood transplantation in non-remission acute myeloid leukaemia: A nationwide retrospective study. Br J Haematol. 2023;201:106-113.<br /> (© 2022 British Society for Haematology and John Wiley & Sons Ltd.)